1. Introduction

Cross-border enforcement of biotechnology judgments refers to the legal process through which a judgment delivered by a court in one country is recognised and enforced by the courts or competent authorities of another country in disputes involving biotechnology, pharmaceuticals, genetic engineering, clinical trials, biological materials, medical devices, genomic information, vaccines, artificial intelligence-assisted biotechnology and life-science research.

Biotechnology disputes increasingly involve multiple jurisdictions because research, manufacturing, clinical testing, intellectual property ownership, commercialisation and distribution frequently take place in different countries.

For example, consider a biotechnology company incorporated in India that develops a gene therapy using technology licensed from a US company. Clinical trials take place in Australia, manufacturing occurs in Singapore, and the product is distributed in European markets.

If a court in Australia delivers a judgment requiring compensation for injuries caused by the clinical trial, the successful claimant may need to enforce that judgment against the defendant's assets in India, Singapore or the United States.

This raises several important legal questions:

Whether the foreign court had internationally recognised jurisdiction.

Whether the judgment is final and enforceable.

Whether the foreign judgment is recognised in the country where enforcement is sought.

Whether enforcement violates domestic public policy.

Whether the judgment conflicts with local biotechnology, pharmaceutical or intellectual property legislation.

Whether the judgment can be enforced against assets, patents, licences or commercial interests located abroad.

The central principle is that a foreign biotechnology judgment does not automatically become enforceable worldwide. Its recognition and enforcement depend on applicable treaties, domestic legislation, jurisdictional rules and public-policy limitations.

2. Meaning and Scope of Cross-Border Enforcement

Cross-border enforcement involves two legally distinct processes.

A. Recognition

Recognition means that the enforcing country accepts the legal effect of a foreign judgment.

For example, an Indian court may recognise an Australian judgment determining that a pharmaceutical manufacturer is liable for defective clinical-trial products.

Recognition may establish:

The existence of a legally determined obligation.

The conclusiveness of the foreign court's decision.

The ability to rely on the judgment in subsequent proceedings.

The availability of legal defences based on res judicata.

B. Enforcement

Enforcement means using the domestic legal machinery of the enforcing country to compel compliance with the foreign judgment.

Possible enforcement measures include:

Attachment of bank accounts.

Seizure or sale of commercial assets.

Execution against property.

Recovery of damages and costs.

Enforcement of monetary obligations.

Recognition of injunctions where domestic law permits.

Enforcement of certain orders concerning contractual obligations.

Recognition and enforcement are related but not identical. A judgment may be recognised without every remedy ordered by the foreign court being directly enforceable.

3. Major Categories of Biotech Judgments

Cross-border enforcement can arise from several categories of biotechnology litigation.

An important distinction is that not all biotechnology judgments receive the same treatment. A monetary judgment concerning breach of a research contract may be treated differently from an injunction affecting a foreign patent or an order regulating biological materials.

4. International Legal Framework

A. Hague Convention on the Recognition and Enforcement of Foreign Judgments in Civil or Commercial Matters, 2019

The Hague Judgments Convention 2019 provides an international framework for recognising and enforcing qualifying foreign civil and commercial judgments.

Its relevance to biotechnology includes:

Pharmaceutical commercial disputes.

Contractual biotechnology disputes.

Certain product-liability claims.

Research and development agreements.

Commercial damages claims.

Certain disputes involving distribution and licensing arrangements.

However, the Convention contains important exclusions.

Article 2 excludes, among other matters, intellectual property rights, with a limited exception concerning copyright and related rights, as well as certain privacy and competition matters.

Consequently, a judgment concerning ordinary pharmaceutical contract damages may potentially fall within its scope, whereas a judgment determining the validity of a biotechnology patent generally does not.

The Convention also establishes conditions concerning jurisdiction, recognition and refusal of enforcement.

B. Hague Convention on Choice of Court Agreements, 2005

The Hague Choice of Court Convention 2005 concerns judgments arising from qualifying exclusive choice-of-court agreements.

It may be relevant where biotechnology companies agree that disputes concerning:

Pharmaceutical supply contracts.

Biotechnology licensing.

Research collaboration.

Clinical-trial services.

Commercial distribution.

will be decided exclusively by the courts of a specified country.

However, its scope is subject to exclusions, including certain intellectual property disputes and other specified categories.

C. New York Convention, 1958

The New York Convention 1958 is important where biotechnology disputes are resolved through arbitration.

Strictly speaking, it concerns arbitral awards, not court judgments.

For example, an international arbitration award concerning breach of a pharmaceutical manufacturing agreement may be enforceable under the Convention, subject to its requirements.

It should therefore not be confused with the enforcement of foreign court judgments.

D. Brussels I Recast Regulation

The Brussels I Recast Regulation (Regulation EU No. 1215/2012) provides a framework for recognition and enforcement of civil and commercial judgments between participating EU Member States.

It is relevant to cross-border pharmaceutical, clinical-trial and commercial biotechnology litigation.

However, intellectual property jurisdiction and patent validity disputes require special consideration under the Regulation.

E. National Laws

Where no applicable international convention governs the dispute, enforcement generally depends on domestic law.

Important examples include:

India's Code of Civil Procedure, 1908.

United States state and federal recognition laws.

Australia's Foreign Judgments Act 1991.

United Kingdom's Administration of Justice Act 1920 and Foreign Judgments (Reciprocal Enforcement) Act 1933, where applicable.

Domestic civil procedure legislation in other jurisdictions.

5. Indian Legal Framework for Enforcement of Foreign Biotech Judgments

India provides an important example of a domestic legal system that regulates foreign judgments through the Code of Civil Procedure, 1908 (CPC).

Three provisions are particularly significant.

A. Section 13 CPC – When Foreign Judgments Are Not Conclusive

Section 13 establishes the general rule that a foreign judgment is conclusive concerning matters directly adjudicated between the same parties, subject to six exceptions.

The six statutory exceptions are:

IndiaCode+1

Importance for biotechnology: A judgment concerning clinical-trial compensation, defective biological products or genomic-data misuse must satisfy the statutory requirements before it can receive conclusive effect in India.

B. Section 14 CPC – Presumption Regarding Foreign Jurisdiction

Section 14 creates a rebuttable presumption that a certified copy of a foreign judgment was delivered by a court of competent jurisdiction.

The party challenging jurisdiction can rebut that presumption by demonstrating the absence of jurisdiction.

For example, if an overseas court issues a judgment against an Indian biotechnology research company, the company may challenge recognition by demonstrating that the foreign court lacked jurisdiction under the applicable legal principles.

IndiaCode

C. Section 44A CPC – Execution of Decrees from Reciprocating Territories

Section 44A provides a simplified execution mechanism for qualifying decrees of superior courts in notified reciprocating territories.

Under this provision:

A certified copy of the foreign decree must be filed before the competent District Court.

A certificate showing the extent of satisfaction or adjustment must accompany it.

The decree may be executed in India as though it had been passed by the District Court.

The decree remains subject to the exceptions under Section 13.

The provision is particularly relevant to monetary judgments against pharmaceutical manufacturers, biotechnology licensees and research organisations.

A significant limitation is that Section 44A is not a universal enforcement mechanism for every foreign judgment. The relevant territory and superior court must satisfy the statutory requirements.

IndiaCode+1

D. Section 47 CPC – Questions Relating to Execution

Section 47 concerns questions arising between parties to the proceedings, or their representatives, relating to the execution, discharge or satisfaction of the decree.

In biotechnology litigation, this may involve disputes concerning:

Whether compensation has already been paid.

Whether the judgment debt has been partially satisfied.

Whether interest has been calculated correctly.

Whether particular assets can be attached.

Whether the execution process exceeds the decree.

E. Foreign Judgments from Non-Reciprocating Territories

Where the foreign judgment originates from a non-reciprocating territory, Section 44A's simplified execution procedure is unavailable.

The judgment creditor will ordinarily need to institute a fresh suit in India based on the foreign judgment, subject to the CPC, limitation requirements and other applicable rules.

The foreign judgment may provide a basis for the claim if it satisfies Section 13.

This distinction is particularly important for biotechnology companies operating between India and countries whose judgments are not covered by India's reciprocating-territory arrangements.

6. Important Judicial Decisions and Case Laws

There is no comprehensive body of reported decisions exclusively concerning worldwide enforcement of foreign biotechnology judgments. The following cases establish the general principles that apply to biotechnology disputes.

Case 1: International Woollen Mills v. Standard Wool (U.K.) Ltd. (2001) 5 SCC 265

Supreme Court of India

Facts:

The dispute concerned enforcement in India of an English foreign money decree. The enforceability of the decree was challenged because it had not been given on the merits of the case.

Legal issue:

Whether a foreign decree that was not given on the merits could be executed in India under Section 44A CPC.

Decision:

The Supreme Court held that a foreign judgment must satisfy Section 13(b). An ex parte judgment is not automatically unenforceable, but a decree that does not represent an adjudication on the merits cannot be enforced under the relevant statutory framework.

Biotechnology relevance:

Suppose a pharmaceutical company obtains an overseas damages judgment against an Indian manufacturer without the foreign court examining the substantive liability.

The manufacturer may challenge enforcement under Section 13(b).

However, mere absence of the defendant does not automatically establish that the foreign judgment was not given on the merits.

Legal principle: Substantive judicial determination is essential for conclusiveness under Section 13(b).

Case 2: Alcon Electronics Pvt. Ltd. v. Celem S.A. (2017) 2 SCC 253

Supreme Court of India

Facts:

An English court made an order concerning a jurisdictional challenge in patent-infringement litigation. The order included an award of costs against the unsuccessful party.

The successful party sought execution of the costs order in India.

Legal issue:

Whether the English court's order could be treated as an executable foreign judgment under Sections 13 and 44A CPC.

Decision:

The Supreme Court accepted that the order was enforceable. The parties had received an opportunity to present their arguments, and the foreign court had adjudicated the jurisdictional issue.

The Court also recognised that an order, rather than only a final money decree, may fall within the relevant definition of an executable judgment or decree.

Biotechnology relevance:

Consider an Indian biotechnology company involved in foreign patent litigation concerning a gene-editing technology.

If an overseas court makes an enforceable costs order after hearing the parties, the order may be capable of execution in India, subject to Section 44A and the other statutory requirements.

Legal principle: A foreign judicial order can be enforceable even where it does not finally determine the underlying patent dispute.

National Digital Library of India+1

Case 3: Satya v. Teja Singh (1975) 1 SCC 120

Supreme Court of India

Facts:

The case involved a foreign divorce decree obtained through disputed assertions concerning the parties' residence and jurisdiction.

Legal issue:

Whether a foreign judgment could be recognised where the foreign court's jurisdiction was obtained through fraudulent representations.

Decision:

The Supreme Court examined the jurisdictional and fraud exceptions under Section 13 CPC and refused to treat a judgment obtained through such fraudulent circumstances as conclusive.

Biotechnology relevance:

A biotechnology company cannot necessarily rely on a foreign judgment obtained by falsely representing its place of incorporation, principal place of business or other jurisdictionally significant facts.

Similarly, fraudulent representations concerning the location of clinical trials or the parties' contractual relationship may become relevant to an enforcement challenge.

Legal principle: Fraud affecting jurisdiction or the integrity of the foreign proceedings may defeat recognition.

Case 4: R. Viswanathan v. Rukn-ul-Mulk Syed Abdul Wajid AIR 1963 SC 1

Facts and legal issue:

The Supreme Court examined the principles governing the jurisdiction of foreign courts and the recognition of foreign judgments.

Decision:

The decision explains that foreign jurisdiction must be examined according to the applicable rules of private international law rather than merely accepting the foreign court's own assertion of jurisdiction.

Biotechnology relevance:

A foreign court's decision against an Indian pharmaceutical company must be examined to determine whether the court possessed internationally recognised jurisdiction.

For example, the mere fact that a pharmaceutical product was sold somewhere in a foreign country may not, by itself, settle every question concerning jurisdiction over a foreign manufacturer.

Legal principle: International jurisdiction is a separate requirement for recognition of foreign judgments.

Case 5: GAT v. LuK (Case C-4/03, 2006)

Court of Justice of the European Union

Facts:

The dispute involved patent infringement and questions concerning patent validity in cross-border litigation.

Legal issue:

Whether courts of a country other than the patent-registration country could determine patent validity in circumstances involving the exclusive jurisdiction rules.

Decision:

The Court of Justice interpreted the exclusive jurisdiction provisions concerning the registration and validity of patents.

Biotechnology relevance:

Suppose a biotechnology company obtains a foreign judgment concerning the validity of an Indian biotechnology patent.

The judgment cannot simply override the jurisdiction allocated to Indian courts concerning the validity of an Indian-registered patent.

This is particularly important for patents involving:

CRISPR gene-editing technology.

Pharmaceutical compounds.

Biologically engineered products.

Genetic diagnostic methods.

Biotechnology manufacturing processes.

Legal principle: Patent validity is territorially sensitive and subject to exclusive jurisdiction rules.

Case 6: Solvay v. Honeywell (Case C-616/10, 2012)

Facts:

The case involved multinational patent-infringement proceedings and applications for provisional measures in different jurisdictions.

Legal issue:

The Court considered the scope of jurisdiction for provisional measures in cross-border patent disputes.

Decision:

The Court examined how national courts could exercise jurisdiction in relation to provisional measures affecting alleged patent infringement across different states.

Biotechnology relevance:

A biotechnology company may obtain an injunction in one country preventing the sale of a disputed biological product.

Whether that injunction can have practical or legal effect in another country depends on the applicable jurisdictional and enforcement rules.

Legal principle: Cross-border patent remedies must respect the territorial and jurisdictional structure of intellectual property law.

Case 7: R. Viswanathan v. Rukn-ul-Mulk Syed Abdul Wajid (1963) 3 SCR 22

Supreme Court of India

Facts:

The dispute concerned the effect of foreign judicial proceedings upon property situated outside the territorial jurisdiction of the foreign court.

Decision:

The Supreme Court explained that foreign judgments must satisfy the requirements of competent jurisdiction and minimum standards of natural justice.

A foreign court cannot automatically determine rights in immovable property situated outside its territorial jurisdiction in a manner binding upon the courts of that other country.

Biotechnology relevance:

The principle is relevant when foreign judgments purport to determine ownership or control of assets situated in India, including:

Biotechnology manufacturing facilities.

Physical research infrastructure.

Biological storage facilities.

Property containing biobank infrastructure.

Legal principle: Foreign judicial authority is subject to territorial limitations and the jurisdictional rules of the enforcing state.

Indian Kanoon+1

Case 8: Satya v. Teja Singh (1975) 1 SCC 120

Facts:

A foreign divorce decree had been obtained by a husband who made misleading representations concerning his residence and jurisdiction.

Decision:

The Supreme Court examined the jurisdictional basis of the foreign judgment and rejected reliance on a foreign decree obtained through fraudulent jurisdictional representations.

Biotechnology relevance:

Suppose a pharmaceutical manufacturer deliberately provides false information about its corporate establishment to obtain a favourable foreign judgment.

If the false information is material to jurisdiction or the proceedings, the enforcing court may examine whether the judgment should be denied recognition under the fraud exception.

Legal principle: Foreign judgments obtained through jurisdictional fraud are not automatically entitled to recognition.

Indian Kanoon

Case 9: Solvay SA v. Honeywell Fluorine Products Europe BV (Case C-616/10, 2012)

Court: Court of Justice of the European Union.

Decision and importance:

The Court considered cross-border patent infringement proceedings, multiple defendants, exclusive jurisdiction concerning patent validity and provisional protective measures.

The judgment demonstrates that patent litigation involving multiple countries requires careful consideration of the territorial jurisdiction of courts.

Biotechnology relevance:

This principle becomes important when a company seeks to enforce a foreign injunction against the sale of a biotechnology product protected by patents in several countries.

A judgment concerning infringement in one country cannot automatically establish infringement of patents in every other country.

EUR-Lex+1

7. Application of the Hague 2019 Convention to Biotechnology Judgments

The Hague 2019 Convention deserves particular attention because it establishes a framework for the circulation of qualifying civil and commercial judgments.

Its provisions are especially relevant to biotechnology companies involved in international commercial activities.

Article 1 – Scope

The Convention applies to recognition and enforcement of judgments in civil or commercial matters between contracting states.

For example, a qualifying judgment concerning breach of an international pharmaceutical supply contract may fall within its scope.

Article 2 – Excluded Matters

Article 2 excludes intellectual property and privacy matters, among other categories.

This creates an important distinction:

The classification depends on the actual subject matter of the proceedings, not simply the fact that biotechnology is involved.

Article 4 – General Recognition and Enforcement

Article 4 establishes that:

A qualifying judgment from one contracting state is to be recognised and enforced in another.

The enforcing court must not reconsider the merits.

The judgment must have effect in the state of origin.

Enforcement requires that the judgment be enforceable in the state of origin.

Article 5 – Bases for Recognition and Enforcement

Article 5 provides recognised jurisdictional connections, including:

Habitual residence of the defendant.

Defendant's principal place of business in certain circumstances.

Express consent to jurisdiction.

Participation in proceedings without timely jurisdictional objection.

Contractual place of performance.

Certain tortious claims involving death, physical injury or property damage.

These grounds may be relevant to cross-border clinical-trial injuries and defective biotechnology products.

Article 7 – Grounds for Refusal

Recognition or enforcement may be refused on specified grounds, including:

Insufficient notice to the defendant.

Fraud.

Manifest incompatibility with the enforcing state's public policy.

Conflict with a relevant choice-of-court agreement.

Inconsistency with certain earlier judgments.

Article 9 – Severability

A court may recognise and enforce only the severable part of a judgment that qualifies for enforcement.

For example, a judgment might contain both an enforceable commercial damages award and a portion concerning an excluded intellectual property issue.

Article 10 – Damages

The enforcing court may refuse enforcement of damages, including punitive or exemplary damages, to the extent that they do not compensate for actual loss or harm.

This is particularly important in pharmaceutical litigation involving substantial punitive damages.

Article 12 – Documents

The applicant must provide the necessary documentation, including a certified copy of the judgment and, where required, proof of service and enforceability in the originating state.

#41 - Full text+1

Important qualification: The Convention only operates between states for which it is in force and applicable to the relevant relationship and proceedings. It should not be assumed to govern enforcement in India merely because the judgment originates from a foreign country.

8. Major Challenges in Cross-Border Enforcement of Biotech Judgments

A. Jurisdictional Conflicts

Biotechnology litigation frequently involves several countries simultaneously.

For example:

Research takes place in Australia.

The defendant is incorporated in India.

The pharmaceutical product is manufactured in Singapore.

The injured patient resides in Germany.

Determining which court has internationally recognised jurisdiction becomes difficult.

A judgment may be valid in the country of origin but fail the jurisdictional requirements of the enforcing country.

B. Differences in Biotechnology Legislation

Different countries have different regulatory standards governing:

Genetic engineering.

Clinical-trial approvals.

Human biological materials.

Gene therapy.

Pharmaceutical safety.

Biological product manufacturing.

Genetic-data protection.

A judgment delivered under one regulatory system may conflict with mandatory laws in another jurisdiction.

C. Public Policy Exception

Public policy is an important limitation on foreign judgment enforcement.

An enforcing court may refuse recognition where enforcement would be manifestly incompatible with fundamental domestic legal principles.

Biotechnology-related examples include:

Enforcement of obligations arising from unlawful human experimentation.

Judgments requiring activities prohibited by domestic biosafety legislation.

Orders conflicting with fundamental protections concerning human dignity.

Orders that violate mandatory restrictions on human biological materials.

However, public policy is not a general licence to reconsider every foreign judgment simply because the enforcing court would have decided the matter differently.

D. Intellectual Property Territoriality

Biotechnology patents are territorial rights.

A patent registered in India does not automatically confer patent protection in the United States, Germany or Japan.

Consequently, a foreign judgment concerning patent infringement may not automatically establish infringement in India.

This creates difficulties involving:

Gene-editing patents.

Pharmaceutical compositions.

Diagnostic technologies.

Biological manufacturing methods.

Genetically modified organisms.

E. Enforcement of Non-Monetary Judgments

Monetary judgments are generally easier to enforce than non-monetary orders.

Consider a foreign judgment requiring a biotechnology company to:

Destroy biological samples.

Stop a clinical trial.

Disclose genomic information.

Transfer biological materials.

Withdraw a genetically modified product.

Stop manufacturing a particular pharmaceutical product.

The enforcing court must examine whether its domestic law permits enforcement of the particular remedy.

Recognition of the foreign judgment does not necessarily mean that the foreign court's order can be implemented directly.

F. Confidentiality and Trade Secrets

Biotechnology companies invest substantial resources in proprietary scientific information.

A foreign judgment may require disclosure of:

Genetic sequences.

Manufacturing processes.

Research protocols.

Clinical-trial datasets.

Proprietary biological materials.

The enforcing court must consider the judgment alongside domestic confidentiality, trade-secret and data-protection laws.

G. Differences in Damages and Compensation

Different countries apply different standards for:

Compensatory damages.

Punitive damages.

Medical injury compensation.

Future medical expenses.

Loss of earning capacity.

Research-related injury.

Article 10 of the Hague 2019 Convention specifically addresses damages that do not compensate for actual loss or harm.

This may create difficulties where a foreign judgment awards substantial exemplary damages.

H. Corporate Restructuring and Asset Protection

Biotechnology companies frequently operate through multinational corporate groups.

A judgment against a subsidiary does not automatically become enforceable against its parent company.

The enforcing court must examine the separate legal personality of companies and the legal basis for liability.

Corporate restructuring, mergers, insolvency and transfers of intellectual property may further complicate enforcement.

9. Hypothetical Examples of Cross-Border Biotech Judgment Enforcement

Example 1: Foreign Clinical-Trial Injury Judgment

An Australian court awards compensation to a participant injured during a pharmaceutical clinical trial conducted by an Indian biotechnology company.

The company has assets in India.

The claimant seeks enforcement in India.

The Indian court would examine:

Whether the Australian court possessed competent jurisdiction.

Whether the judgment was delivered on the merits.

Whether the defendant received proper notice.

Whether the judgment falls within Section 13 CPC.

Whether Section 44A applies or a separate suit is required.

The claimant cannot assume that the Australian judgment is automatically executable in India.

Example 2: Foreign Gene-Editing Patent Judgment

A US court determines that a biotechnology company infringed a US gene-editing patent.

The patent owner attempts to enforce the judgment in India.

The Indian court must distinguish between:

Monetary liability arising from the US infringement.

The territorial effect of the US patent.

Any attempt to establish infringement of an Indian patent.

Any injunction affecting activities within India.

The US judgment cannot, merely by its existence, determine the validity or infringement of an Indian patent.

Example 3: Genomic Data Misuse Judgment

A European court orders a biotechnology company to compensate individuals for unlawful disclosure of genomic data.

The company has assets in India.

The claimant seeks enforcement in India.

The enforcing court must consider the applicable foreign judgment recognition rules, including jurisdiction, finality, fraud, natural justice and public policy.

An important complication is that privacy matters are excluded from the Hague 2019 Judgments Convention. Therefore, enforcement would need to rely on another applicable legal framework.

Example 4: Pharmaceutical Product Liability

A court in the United Kingdom awards damages against a pharmaceutical manufacturer for injuries caused by a defective biological medicine.

The manufacturer maintains commercial assets in India.

The judgment creditor must establish:

The legal status of the judgment in the UK.

The basis for recognition in India.

Compliance with Section 13 CPC.

The applicability of Section 44A or the fresh-suit procedure.

The availability of attachable assets.

10. Practical Procedure for Enforcing Foreign Biotech Judgments in India

The following sequence provides a practical enforcement framework.

Enforcement process

Obtain the foreign judgment

Obtain a complete certified copy of the judgment and relevant court records.

Establish enforceability

Demonstrate that the judgment has legal effect and is enforceable in the country of origin.

Identify the enforcement jurisdiction

Locate the defendant's assets and determine the competent Indian court.

Determine reciprocating status

Establish whether the originating territory and court qualify under Section 44A CPC.

Examine Section 13

Assess jurisdiction, merits, applicable Indian law, natural justice and fraud.

File the execution application or fresh suit

Use Section 44A where available; otherwise pursue the appropriate independent civil action.

Address objections

Respond to challenges involving public policy, jurisdiction, limitation and satisfaction of the decree.

Execute the judgment

Seek legally available attachment, sale or other execution remedies against the judgment debtor's assets.

Documents generally required

Certified copy of the foreign judgment.

Evidence of service of proceedings.

Evidence of finality or enforceability, as applicable.

Certified translation, where necessary.

Details of the judgment debtor.

Information concerning assets in India.

Calculation of outstanding damages and interest.

Relevant contractual and procedural documents.

The applicable procedural requirements must be checked against the particular originating country and enforcement route.

11. Relationship Between Biotech Regulatory Law and Foreign Judgments

Cross-border enforcement becomes especially complicated where a judgment involves public regulatory authorities.

For example, a foreign court may determine that a pharmaceutical manufacturer is liable for defective medicines.

However, the foreign judgment does not automatically:

Cancel an Indian drug-manufacturing licence.

Override an Indian regulatory approval.

Authorise the importation of restricted biological materials.

Compel the Indian regulator to grant marketing approval.

Replace domestic biosafety certification.

Civil liability and regulatory authorisation are legally distinct matters.

The enforcement of private rights cannot ordinarily substitute for statutory regulatory decisions.

This distinction is particularly important under India's:

Drugs and Cosmetics Act, 1940.

New Drugs and Clinical Trials Rules, 2019.

Biological Diversity Act, 2002.

Environment (Protection) Act, 1986.

Patents Act, 1970.

Digital Personal Data Protection Act, 2023, subject to applicable commencement and implementation provisions.

12. Critical Legal Issues for Future Development

The increasing internationalisation of biotechnology creates several emerging legal issues.

13. Suggestions for Legal and Regulatory Reform

Several reforms could improve the effectiveness of cross-border enforcement.

1. International judicial cooperation: Countries should strengthen cooperation concerning recognition and enforcement of commercial biotechnology judgments.

2. Clear jurisdictional standards: Courts should develop predictable standards for disputes involving multinational clinical trials and pharmaceutical distribution.

3. Specialised enforcement procedures: Procedural guidance could address scientific evidence, biological materials and complex pharmaceutical damages.

4. Protection of fundamental rights: Enforcement mechanisms should preserve human dignity, informed consent, privacy and biosafety protections.

5. Intellectual property coordination: Countries should improve judicial cooperation while preserving the territorial nature of patent rights.

6. Recognition of electronic evidence: Courts should develop reliable methods for verifying international clinical-trial records, digital signatures and electronic scientific evidence.

7. Transparent damages assessment: International standards could improve the assessment of pharmaceutical injuries and research-related compensation.

8. Protection against inconsistent judgments: Better judicial coordination could reduce contradictory decisions in multinational biotechnology disputes.

14. Conclusion

Cross-border enforcement of biotechnology judgments is an important intersection of private international law, civil procedure, intellectual property law, pharmaceutical regulation, biosafety and human-rights protection.

The principal legal challenge is balancing the international effectiveness of judicial decisions with the sovereignty and mandatory legal requirements of the enforcing country.

In India, Sections 13, 14 and 44A of the Code of Civil Procedure, 1908 provide the central statutory framework for examining foreign judgments.

The decisions in International Woollen Mills, Alcon Electronics, Satya v. Teja Singh and R. Viswanathan establish important principles concerning merits, jurisdiction, fraud and natural justice.

Internationally, the Hague 2019 Judgments Convention and the Brussels I Recast framework provide additional models for facilitating the circulation of qualifying civil and commercial judgments. Their scope and territorial application must nevertheless be examined carefully. In particular, India is not a party to the Hague 2019 Judgments Convention, so it cannot presently be relied upon as the direct treaty basis for enforcing a judgment in India.

#12 - Status table+2

Ultimately, an effective enforcement framework must facilitate international compensation and commercial accountability without allowing foreign judgments to override domestic patent rights, biosafety requirements, regulatory powers or fundamental legal protections.

15. Important Case Law Revision Table

Research note: These authorities establish general principles of foreign judgment recognition and patent jurisdiction. They should not be represented as direct decisions on the enforcement of biotechnology judgments unless a particular case actually concerns that subject.

16. Important Statutory and Treaty References

Code of Civil Procedure, 1908 – Sections 13, 14, 44A and 47.

Hague Convention on Recognition and Enforcement of Foreign Judgments, 2019 – Articles 1–12.

Hague Convention on Choice of Court Agreements, 2005.

New York Convention, 1958 – Foreign arbitral awards.

Brussels I Recast Regulation (EU) No. 1215/2012.

Patents Act, 1970 (India).

Drugs and Cosmetics Act, 1940 (India).

New Drugs and Clinical Trials Rules, 2019 (India).

Digital Personal Data Protection Act, 2023 (India).

Primary research resources:

Indian Code of Civil Procedure, 1908 – India Code.

Hague 2019 Judgments Convention – Full Text.

Hague Conference – Judgments Convention.

Alcon Electronics – Supreme Court judgment.

Satya v. Teja Singh – Supreme Court judgment.